PT  - JOURNAL ARTICLE
AU  - Vinall, Maria
ED  - Leifke, Eckhard
TI  - TAK-875 Reduces HbA1C in Patients with T2DM
DP  - 2011 Dec 01
TA  - MD Conference Express
PG  - 10--10
VI  - 11
IP  - 11
4099  - http://mdc.sagepub.com/content/11/11/10.short
4100  - http://mdc.sagepub.com/content/11/11/10.full
AB  - TAK-875 is a selective G-protein-coupled receptor 40 (GPR40) agonist that is being developed as an adjunct therapy to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus. Results of a Phase 2 [NCT01007097] trial that has shown the glucose-lowering efficacy, safety, and tolerability of TAK-875 in a clinical setting are discussed.